BioMarin Pharmaceuticals Inc (BMRN) Dividend History

BioMarin Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare genetic diseases. Founded in 1997, it specializes in treatments for conditions such as enzyme deficiencies, genetic disorders, and other underserved medical needs, offering its products primarily in the areas of neurology, inherited metabolic disorders, and hematology.

105 Digital Drive, Novato, CA, 94949
Phone: (415) 506-6700

Dividend History

BioMarin Pharmaceuticals Inc currently does not pay dividends

Company News

Here Are All 6 Stocks I've Bought Through 5 Months of 2025

The article discusses the stocks that the author has bought during the first five months of 2025, including Pfizer, PubMatic, Sirius XM, Intel, BioMarin Pharmaceutical, and Fastly. The author believes these stocks are undervalued and have long-term growth potential.

The Motley Fool

Featured Companies: FSLY INTC PFE PUBM SIRI
Joshua Grass, John Kelly, and Lauren Daniel Join 5AM Ventures

5AM Ventures, a leading life science venture capital firm, has announced the addition of three key leaders to its team: Joshua Grass as Venture Partner, John Kelly as Partner, Chief Financial Officer and Chief Operating Officer, and Lauren Daniel as Chief Compliance Officer and Deputy General Counsel. These appointments aim to strengthen the firm's investment capabilities, financial and operational governance, and regulatory oversight as it continues to expand its portfolio.

GlobeNewswire Inc.
6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility

The author discusses 6 stocks he purchased during the recent market volatility, including Pfizer, Sirius XM, Intel, Fastly, BioMarin Pharmaceutical, and PubMatic, citing their apparent price dislocations and long-term potential.

The Motley Fool

Featured Companies: FSLY INTC PFE PUBM SIRI
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients

BioMarin's Palynziq significantly lowered blood Phe levels in adolescent patients with phenylketonuria (PKU) compared to diet alone. BioMarin plans to submit data for label expansion to health authorities this year.

Benzinga
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today

BioMarin Pharmaceutical reported strong Q4 2024 results, with revenue up 16% and adjusted net income nearly doubling. The company attributed the gains to rising demand for its enzyme therapies and large-scale government orders. Management provided positive guidance for 2025, indicating a prosperous year ahead.

The Motley Fool

Dividend data last updated 06/07/2025 15:33:31 UTC